ELISPOT and Fluorospot Assay Market, By Product Type (ELISpot Assay Kits and Fluorospot Assay Kits), By Application (Diagnosis, Drug Discovery and Development, and Research), By End-use [Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), Academic and Research Institutes], and By Region Forecast to 2032

The global Enzyme Linked Immunospot (ELISPOT) and fluorospot assay market size was USD 281.02 Billion in 2022 and is expected to reach USD 561.76 Billion in 2032, and register a rapid revenue CAGR of 8% during the forecast period. Rising demand for Enzyme-Linked Immunospot (ELISPOT) and Fluorospot assays, as chronic diseases including cancer and autoimmune disorders become more common, is a major factor driving market revenue growth. These tests aid in early diagnosis of illnesses, tracking of disease development, and effectiveness of medical interventions. For example, National Cancer Institute has advised against using ELISpot tests to find immune responses to cancer antigens in treatment studies. In addition, prevalence of infectious diseases such as Human Immunodeficiency Virus (HIV) and tuberculosis is increasing, which is in turn rising demand for these assays. Use of ELISpot and Fluorospot assays allows for identification of disease-specific biomarkers as well as tracking of immune responses to infectious agents.

In addition, need for tailored treatment is another factor driving revenue growth of the market. Using diagnostic techniques and targeted treatments that are adapted to each patient's unique demands constitutes personalized medicine. Development of customized medicine depends on the ability of ELISpot and Fluorospot tests to identify disease-specific biomarkers and track immune responses to therapy.

Moreover, technological developments in ELISpot and Fluorospot assays is also expected to drive market revenue growth. Efficiency and precision of these tests are being increased through creation of automated systems and use of multiplexed assays. Demand for these assays is also expected to increase with the release of Digital ELISpot and Fluorospot tests, which allow for automated counting of individual spots.

Furthermore, increasing use of ELISpot and Fluorospot tests for drug Research & Development (R&D) in pharmaceutical and Biotechnology firms is also driving market revenue growth. In clinical trials, these assays are helpful for discovering therapeutic targets, assessing drug efficacy, and tracking immune responses. Demand for these assays is also rising by rising demand for Biologics such as cell treatments and monoclonal antibodies.

However, high cost of ELISpot and Fluorospot tests and requirement for specialist knowledge are major factors, which could restrain market revenue growth. In addition, absence absence of uniformity in assay techniques and variation in findings acquired from different laboratories are other factors, which could restrain market revenue growth.

Government Regulations:

  • The U.S. Food and Drug Administration (FDA) has established guidelines for ELISpot and Fluorospot assays used in clinical diagnostics.
  • The European Commission has adopted regulations to ensure safety, quality and efficacy of ELISpot and Fluorospot assays used in medical testing.
  • The U.S. Centers for Disease Control and Prevention (CDC) has established guidelines for interpreting results of ELISpot and Fluorospot assays used in clinical diagnostics.
  • The U.S. National Institutes of Health (NIH) has established guidelines for Research & Development (R&D) of ELISpot and Fluorospot assays.
  • The World Health Organization (WHO) has issued recommendations for use of ELISpot and Fluorospot assays in Clinical Laboratory.

Key Takeaways

By Product Type Outlook:

The methods ELISpot and Fluorospot tests are frequently used to identify and count the cells that secrete cytokines in response to a particular antigen. These assays have transformed immunology and have important applications in the treatment of cancer, infectious diseases, the creation of Vaccines, and organ Transplantation. The global ELISpot and Fluorospot assay market has been divided into ELISpot assay kits and Fluorospot assay kits based on the product type.

In a number of clinical and scientific situations, the ELISpot test is a potent tool for the study of cytokine-secreting cells, in particular T cells and B cells. The assay is frequently used to track immunological responses to cancer treatment, immunization, and infectious disease prevention. Pre-coated plates, detection antibodies, and other assay-related reagents are frequently included in ELISpot test kits. These kits are simple to use and offer reliable, repeatable results. Because of the variety of applications it may be used for and how simple it is to use, the ELISpot category is anticipated to hold a sizable portion of the global market.

The Fluorospot assay is an adaptation of the ELISpot assay that identifies cytokine-secreting cells using fluorescently labelled antibodies. In comparison to the conventional ELISpot assay, this method has a number of benefits, including improved sensitivity, multiplexing capabilities, and lower variability. Fluorescently labelled detection antibodies, pre-coated plates, and other assay-necessary chemicals are frequently included in fluorospot test kits. Due to the rising need for more sensitive and multiplexed assays, the Fluorospot segment is anticipated to have considerable growth over the course of the projected period.

Due to the rising incidence of infectious diseases and cancer, the rising demand for personalized treatment, and rising investments in R&D activities, the ELISpot and Fluorospot assay market is anticipated to have considerable expansion over the forecast period. The growing use of these assays for drug discovery and development in the pharmaceutical and biotechnology sectors is also anticipated to have a positive impact on the market.

The market for ELISpot and Fluorospot assays is also anticipated to expand as a result of the growing emphasis on precision medicine and the creation of companion diagnostics. These assays enable more targeted and individualized therapy by identifying particular biomarkers that are predictive of illness progression and treatment response.

Geographically, North America is anticipated to rule the ELISpot and Fluorospot assay market due to the region's developed biotechnology and pharmaceutical sectors as well as the rising incidence of chronic diseases. Due to rising investments in R&D activities and the demand for personalized medicine, the Asia Pacific region is anticipated to have considerable growth during the forecast period.

End-use Outlook:

The ELISpot and Fluorospot Assay Market is divided into three groups based on end-use: contract research organizations (CROs), academic institutions, and research centers. The segment of biotechnology and pharmaceutical firms held the biggest revenue share among these groups in 2021, and it is anticipated that it will continue to dominate during the projected period. The rise in need for research and development of efficient diagnostic and treatment options can be ascribed to the rising prevalence of chronic diseases like cancer, autoimmune disorders, and infectious diseases. Moreover, the market expansion is being further fueled by the increased expenditures made in the biotechnology and pharmaceutical industries for research and development activities. A significant element boosting market expansion in this sector is the biotech and pharmaceutical industries' use of ELISpot and Fluorospot assays for drug development and clinical trials.

Throughout the projected period, the contract research organizations (CROs) segment is anticipated to post the greatest revenue CAGR. This industry is expanding as more pharmaceutical and biotechnology businesses outsource their clinical research operations to cut costs and improve research effectiveness. Due to the growing need for precise and dependable diagnostic solutions as well as the expanding need for outsourcing clinical research activities, ELISpot and Fluorospot assays are anticipated to be used by CROs in greater numbers. The expansion of this market is also being fueled by the rising tendency of pharmaceutical and biotechnology businesses outsourcing their drug discovery and development operations.

Throughout the projection period, the academic and research institutes segment is anticipated to experience moderate expansion. The increased emphasis on R&D activities in academic and research institutions, particularly in the fields of immunology, infectious diseases, and cancer research, can be linked to the segment's expansion. It is anticipated that more academic and research institutions would use ELISpot and Fluorospot assays for research and development operations, which will propel market expansion in this sector.

Regional Outlook:

Due to the growing use of ELISpot and Fluorospot Assays in a variety of research activities, the North American market for these assays is also anticipated to experience rapid revenue growth. Demand for high-throughput screening techniques is rising as a result of rising spending in life sciences research and development, which in turn is boosting demand for these assays. Additionally, the market for ELISpot and Fluorospot Assay is expanding in this region due to the rising prevalence of chronic diseases like cancer, autoimmune diseases, and infectious diseases.

ELISpot and Fluorospot Assay market growth in Europe is anticipated to be moderate. The expansion of the pharmaceutical and biotechnology businesses in the area is the main factor driving the demand for these assays. In addition, the region's rising incidence of cancer and infectious disorders is fueling demand for these assays. One of Europe's biggest marketplaces for goods related to industry, food, and drink is the UK. According to the Food and Drink Federation (FDF), the value of produced food and drink to the country's economy was around 32.76 billion USD. As a result, the food and beverage industry has a huge need for trustworthy diagnostic instruments like ELISpot and Fluorospot Assays.

Major Companies and Competitive Landscape

  • Mabtech AB
  • Oxford Immunotec
  • U-CyTech Biosciences
  • Life Technologies Corporation
  • ZeptoMetrix Corporation
  • BD Biosciences
  • Merck KGaA
  • Abcam plc
  • Bio-Rad Laboratories, Inc.
  • Cellular Technology Limited
  • Luminex Corporation

Strategic development:

To strengthen their market position, the leading firms in the ELISpot and Fluorospot Assay market are concentrating on strategic developments. Recent market developments in terms of strategy include:

  • In 2021, Abcam plc and Bio-Techne Corporation established a collaborative partnership to create cutting-edge protein analysis assays. In order to give researchers a complete solution, the partnership will bring together Bio-competence Techne's in protein analysis with Abcam's experience in antibody technology.
  • In 2021, Luminex Corporation and Illumina, Inc. announced a collaboration to create an NGS system for clinical research. The collaboration seeks to combine the MAGPIX equipment from Luminex with Illumina's sequencing technology to offer a complete clinical research solution.
  • Oxford Immunotec declared that its T-SPOT would go on sale in 2020.

New product launches:

  • In 2020, AmpTec GmbH, a supplier of RNA and mRNA synthesis technologies, was acquired by Merck KGaA. The acquisition is anticipated to improve Merck's capability in mRNA-based medicines and vaccines.
  • Bio-Rad Laboratories, Inc. said that their SARS-CoV-2 Total Ab test, a blood test that finds antibodies to the SARS-CoV-2 virus, will be available in 2020. The test, which is based on the business's Bio-Plex technology, is meant to assist in the diagnosis of COVID-19.
  • Mabtech AB: The company debuted a new line of ELISpot and Fluorospot assay kits for the detection of cytokines and other analytes in 2021. The kits have great sensitivity and specificity and can be used for both clinical and research applications.
  • A new line of ELISpot test kits for the detection of cytokines and other biomolecules was introduced by U-CyTech Biosciences in 2020.

Segments Covered in the Report:

By Product Type         

  • ELISpot Assay Kits
  • Fluorospot Assay Kits

By Application

  • Diagnosis
  • Drug Discovery and Development
  • Research

By End-use

  • Biotechnology and Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes

Regional scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Report Detail

  • Report Code:120554
  • No. of Pages:150+
  • Format:Data Book

Proceed To Buy

USD 1599
USD 2999

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers